Experimental CAR t treatment targets root cause of rare nerve disease
NCT ID NCT07573332
First seen Jun 25, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This early-phase trial tests whether a new CAR T cell therapy called CC-97540 is safe for people with a rare autoimmune disease called neuromyelitis optica (NMOSD). The study will enroll 5 adults who are stable on current treatments. Researchers will check for side effects and whether the therapy can eliminate harmful antibodies linked to the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CC-97540 (BMS-986353) CAR T cell therapy
- What this could lead to
- If it works, this could point toward a way to reduce or stop NMOSD relapses without lifelong immune suppression.
- What could go wrong
- This is a very early, tiny phase 1 safety study with only 5 participants. It may not show benefit, and CAR T therapy carries risks like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AQP4+ NMOSD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UT Southwestern
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Genetic clues may forecast multiple sclerosis after vision loss
- Engineered immune cells take aim at autoimmune diseases
- Can virtual training rewire the brain in MS?
- New study aims to understand physical challenges in kids with nerve diseases
- New hope for NMOSD patients: drug aims to slash relapse rate